LUNEL F, VEILLON P, PAYAN C; Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd : 2002 : San Diego, Calif.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. V-235.
and the Fontevraud Study Group; CHU ANGERS, Angers, France
BACKGROUND: To evaluate the predictive value of Total HCV Core antigen assay in treatment of patients with chronic HCV. METHODS: 55 patients were infected by genotype 2 or 3 and received a primary dose of 3 (if HCV RNA < 3 Meq/ml) or 6 million units of interferon alfa-2b thrice weekly for 12 months. Ribavirin was added at month 3 (M), until M12 if hepatitis C virus (HCV) RNA was found positive after M2 of interferon. The viral kinetic was assessed during the follow up by serial measurements of HCV RNA (bDNA 3.0 and Monitor 2.0) and using a new prototype assay designed by Ortho-Clinical Diagnostics which is able to quantify total HCV Core antigen. RESULTS: Sustained virologic response was observed in 65% of the patients (36/55) (61% (23/38) in the group treated by interferon alone and 76% (13/17) with combination therapy). At M1 of interferon treatment, sustained responders to interferon alone or combination therapy had a fall of HCV RNA higher than non responders, 4.23 +/- 1.84 log UI/ml versus 1.35 +/- 1.47 log UI/ml (p < 0.01), respectively. No observed significant difference for the decrease of Total Core antigen was observed. After one month of interferon treatment, the Positive Predictive Value and Negative Predictive Value of sustained response to treatment were, respectively, 100% and 17.4% for HCV RNA disappearance and 97.5% and 37.5% for HCV Core antigen disappearance. CONCLUSIONS: These results suggest that kinetics of viral load and HCV Core antigen are highly predictive of sustained response.
Publication Types:
Keywords:
- Genotype
- Hepacivirus
- Humans
- Interferon Alfa-2b
- Interferons
- Kinetics
- RNA
- RNA, Viral
- Ribavirin
- Viral Load
- genetics
- pharmacokinetics
- therapy
Other ID:
UI: 102267114
From Meeting Abstracts